CHEMOKINE RECEPTOR CXCR4-DIRECTED THERANOSTICS OF ADVANCED LYMPHOPROLIFERATIVE CANCERS BY RADIOPEPTIDE-BASED IMAGING AND THERAPY: THE COLPRIT PHASE I/II STUDY

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517639-35-00

Acronym

COLPRIT-0000-BAS-004

Enrollment

Registered

2024-10-14

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin lymphomas (NHL)

Brief summary

Phase I: Determination of maximum tolerated dose (MTD), Phase II: ORR

Detailed description

Phase I: The dosimetric analysis for the assessment of the radiation dose received by the patient., Phase II: Median PFS, OS, hematopoietic recovery (measured with the time course of CBCs), Safety Endpoints: Frequency and severity of adverse events

Interventions

DRUG[68Ga]Ga-PentixaFor

DRUG[90Y]Y-PentixaTher

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Phase I: Determination of maximum tolerated dose (MTD), Phase II: ORR	—

Secondary

Measure	Time frame
Phase I: The dosimetric analysis for the assessment of the radiation dose received by the patient., Phase II: Median PFS, OS, hematopoietic recovery (measured with the time course of CBCs), Safety Endpoints: Frequency and severity of adverse events	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026